JIPMER Calls for Proposals To 1st Scientific Advisory Committee Meeting 2025

Puducherry- Through a circular, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry has informed about the submission of the proposal in the 1st JIPMER Scientific Advisory Committee Meeting (JSAC) for the year 2025. The last date for submission of proposals (by mail and hard copy) is 14th December 2024 (12:00 PM).

On 9th January 2025 (Thursday), JIPMER is going to organise the 1st meeting of the JIPMER Scientific Advisory Committee (JSAC).

Candidates are instructed to use the combined format containing Section-1 (for JSAC), and Section-2 (for Intramural Research Fund Committee) and fill both sections accordingly. The Format is available under the Research Category on the official website of JIPMER, which is mentioned in the notice.

The participants should ensure that they submit both an original hard copy and a Xerox copy of the research proposal, along with a cover letter addressed to the Dean (Research). The hard copy should be written in 11 font size, with 1.5 spacing and page numbering, using both sides of A4 size paper. If participants fail to submit the research proposal in the given format the proposal will not be accepted and no subsequent modification of the proposals will also not be accepted. However, only citing and listing references as per the International Committee of Medical Journal Editors (ICMJE) style will be accepted.

Candidates are required to mail the scanned copy of the proposal (with all required signatures) in “.pdf format” and the Microsoft Word file of the proposal in “.docx format” (2 attachments) to the official Gmail ID of JIPMER with the subject as “Submission of Initial / Revised proposal by <> for First JSAC 2025 meeting on 09/01/2025”.

The notice further stated that “There can be only one co-investigator from the same department to discourage gift co-investigatorship. It applies to both the department of primary investigator and the department of collaborating investigator”.

To view the circular, click the link below

https://medicaldialogues.in/pdf_upload/jipmer-calls-for-proposals-to-1st-scientific-advisory-committee-meeting-for-2025-263766.pdf

Powered by WPeMatico

Teva to divest Teva-Takeda, its Business Venture in Japan

Telaviv: Teva Pharmaceutical Industries Ltd. has announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.

Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.

“This is another step in our Pivot to Growth strategy to focus the business,” said Mark Sabag, Executive Vice President, International Markets Commercial. “Furthermore, we are confident that this agreement with JKI will ensure the continued delivery of high-quality, affordable medicines to patients in Japan.”

Read also: USFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, Teva

Powered by WPeMatico

Kochi Cardiothoracic Surgeon honoured with Dr SN Tripathy Memorial Oration Award

Kochi: A renowned cardiothoracic surgeon and head of the Department of Minimally Invasive Thoracic Surgery at Sunrise Hospital, has been conferred with the prestigious Dr SN Tripathy Memorial Oration Award at the 79th National Conference of Tuberculosis and Chest Diseases (NATCON 2024), held recently in Jaipur, Rajasthan.

As per the recent media report by TOI, Dr Yusuf is the first thoracic surgeon from Kerala to receive this honour.

Dr Yusuf’s journey in cardiothoracic surgery has been marked by groundbreaking achievements. He graduated as a Cardiothoracic Surgeon from KMC Manipal, where he was awarded the Gold Medal for his exceptional academic performance. His expertise led him to prestigious roles in Ireland and the United Kingdom. There he spent eight years honing his skills in thoracic surgery.

He made history in 1998 by performing the first Coronary Artery Bypass Surgery in the Malabar region at Fathima Hospital. Dr Yusuf pioneered Keyhole Surgery of the Chest (Thoracoscopy) and Mediastinoscopy in Kerala in 1999, revolutionizing the treatment of chest diseases.

This new distinguished recognition celebrates Dr Yusuf’s exceptional dedication and his contributions to the field of tuberculosis and chest diseases in India. His award-winning lecture was titled ‘Tuberculosis – The Phoenix of Thoracic Surgery.’

Also Read: Renowned Endocrinologist Dr M Ashraf Ganie honoured with Subhash Mukherjee Memorial Oration-2023

Medical dialogues had earlier reported that renowned Endocrinologist, Dr M Ashraf Ganie has been honoured with the “Subhash Mukherjee Memorial” Oration-2023 by the prestigious Endocrine Society of India (ESI). The prestigious Oration has been awarded to Dr Ashraf for his extensive research in the field of endocrine & metabolic disorders.

Dr Ashraf is currently a Professor of Endocrinology and Metabolism and Sub-Dean Research at SKIMS Srinagar. At SKIMS, Dr Ashraf has spearheaded various initiatives aimed at fostering a robust research environment, including the establishment of the Department of Clinical Research and the Medical Research Unit, among other similar facilities.

Powered by WPeMatico

Weeekly OPD service provided at AIIMS Satellite Centre Balasore: MoS Health

Balasore: Union Minister of State for Health, Shri Prataprao Jadhav recently informed the Lok Sabha about the status of the AIIMS Satellite Centre at Balasore. While the construction of the Outpatient Block was completed in 2022, the centre has not yet become fully operational, despite the infrastructure being in place.

In addition to the AIIMS Balasore Satellite Centre, the government is also working on the expansion of healthcare facilities under PMSSY.

Also Read: No Plans for AIIMS in Sheohar, Bihar: MoS Health tells Lok Sabha

MoS Health, Prataprao Jadhav was responding to questions posed by Vinod Kumar Bind and Shri Pratap Chandra Sarangi, Members of Parliament, who wanted to know whether it is true that AIIMS Satellite Centre has not been fully operational even after having completed more than ten years, if so, the details therefor;

He also seeks to know, whether the Government is aware of the fact that the entire infrastructure is susceptible to being damaged is not in use and if so, the details thereof; 

Furthermore, he inquired about the time by which it is likely to be made fully operational along with the steps taken/proposed to be taken in this regard.

In response to these questions, MoS Health informed that in the new AIIMS set up under PMSSY, the construction of Out Patient Block of Satellite Centre of AIIMS Bhubaneswar at Balasore was completed in 2022 and currently Outpatient Services are provided for two days a week by the doctors and staff from AIIMS Bhubaneswar. More than 20,000 patients have availed of the service. Approval has also been accorded for the setting up of a 280-bed Satellite Centre of AIIMS Rishikesh at Udham Singh Nagar, Uttarakhand at a project cost of Rs.494.00 crore. The project work started in August 2023.

Also Read:14 Medical Colleges approved for MP districts, 10 Operational: MoS Health informs Lok Sabha

Powered by WPeMatico

Gilead Sciences, Tubulis ink pact to develop ADC candidate for select solid tumor target

Foster City: Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.

Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.

“As we expand our oncology portfolio to address the greatest gaps in care, accessing novel technologies is critical to advancing our pipeline,” said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences. “With Gilead’s ongoing focus on innovating with next-generation therapies and combinations, we are excited to partner with Tubulis to explore a range of solutions that may help increase the therapeutic value of the ADC modality.”

“Gilead has established a long track record of developing drugs that provide a significant step-up in therapeutic value, making them a great collaborator for leveraging our technology platforms, in line with our vision of fundamentally changing the ADC landscape,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “Tubulis remains primarily focused on driving value through our own clinical development programs while selectively building partnerships with leaders in the industry.”

Read also: Gilead Sciences inks pacts with Dr Reddy’s Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir

Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million. In addition, Tubulis will be eligible for development and commercialization milestone payments totaling up to $415 million, plus mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. Tubulis will lead early-stage research and development activities for the ADC program. If Gilead exercises its option to exclusively license the program, Gilead will be responsible for further development and commercialization activities for all products resulting from the collaboration.

Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Tubulis is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.01.

Powered by WPeMatico

Not Adhoc! Recruit Regular Assistant Professors in Odisha Medical Colleges: HC Tells State

Cuttack: Terming the State Government’s practice of appointing Assistant Professors on a contractual basis in the government medical colleges as “unsustainable”, the Orissa High Court recently directed the State Government to expedite the regular recruitment of posts of Assistant Professors through the Odisha Public Service Commission (OPSC).

“This Court underscores that the persistent practice of appointing contractual employees to positions such as Assistant Professor in medical institutions is unsustainable. These posts must be filled through regular appointments to ensure the integrity and stability of the academic and medical framework. The Government is directed to ensure that the OPSC initiates the recruitment process as expeditiously as possible for filling these positions with regular appointees, thereby addressing the prevailing culture of complacency and ad-hoc arrangements in public service,” observed the HC bench comprising Justice S K Panigrahi.

These observations were made by the Court while considering the plea by a Medical Practitioner who is serving as an Assistant Professor in the Department of Anaesthesiology on a contractual basis. He challenged the advertisement issued under the Order dated 08.05.2024 by the Dean and Principal of MKCG Medical College and Hospital, Berhampur, for filling the post of Assistant Professor in the Department of Anaesthesiology, a position currently held by the petitioner on deputation.

The counsel for the petitioner submitted that he was selected by the Odisha Public Service Commission (OPSC) and was appointed as Assistant Surgeon/Medical Officer under the DHS cadre within the Health and Family Welfare Department, Government of Odisha. Subsequently, following a selection process, he was deputed to the post of Assistant Professor in the Department of Anesthesiology at MKCG Medical College and Hospital, Berhampur, pursuant to an Order dated 01.01.2020 issued by DMET, Odisha.

Also Read: Orissa HC adjourns PIL alleging inadequate health services in Govt Hospitals

Further, it was submitted that the Government of Odisha on 04.03.2017 communicated the modalities for appointing Assistant Professors in new government medical colleges, which could now be filled up on a contractual or deputation basis. Clause 10 of the said modalities provided that in-service OMHC cadre doctors selected for such regular Assistant Professor posts would continue in their positions until the posts are filled on a regular basis.

Subsequently, the Odisha Government issued a resolution on 26.02.2019, prescribing guidelines for engaging Assistant Professors, Associate Professors, and Professors in government medical and dental colleges on a contractual basis.

As per the Clause 10 of the Government’s letter dated 04.03.2017, a doctor appointed as an Assistant Professor on deputation against a regular post would be reverted to their parent cadre once the position is filled up through regular appointment. However, the resolution dated 26.02.2019 did not specify a tenure for contractual or deputation appointments.

Referring to these, the petitioner’s counsel argued that he was entitled to continue in the said post, pursuant to the order dated 01.01.2020, until the post was filled through a regular selection process.

The petitioner contended that while serving as Assistant Professor on deputation at MKCG Medical College, the medical college issued an advertisement dated 08.05.2024 to fill up his post on a contractual or deputation basis. Although the advertisement listed three vacancies, four were shown during counseling, despite only two of the eleven sanctioned posts being genuinely vacant.

In his plea before the High Court, the petitioner contended that as per the letter dated 04.03.2017, he was entitled to continue in his post until it was filled through a regular appointment. Therefore, the petitioner asserted that the move to replace him was legally untenable.

On the other hand, the college submitted that the petitioner belonged to the DHS/OMHS cadre and was appointed to meet the NMC staffing requirements. His deputation as Assistant Professor began on 31.01.2020 and ended on 30.01.2024. The DMET, Odisha, initially directed relieving deputed Assistant Professors completing 4-year tenures (through the letter dated 06.03.2023) but kept the order in abeyance (through the letter dated 13.03.2023) due to impending NMC inspections.

The college clarified that the provisional vacancy list was prepared, reflecting anticipated vacancies and aiming to provide opportunities to fresh candidates after securing NMC recognition.

Further, it was stated that the deputed/contractual Assistant Professors with completed 4-year tenures are eligible for promotion to Associate Professor roles in other medical colleges under the 25.04.2022 Government Resolution. Therefore, the petitioner might apply for the position of Associate Professor in other colleges, submitted the college.

DMET, Odisha directed all Deans and Principals to relieve Assistant Professors serving on contractual or deputation basis who have completed their four-year tenure. Consequently, the provisional vacancy list was published to provide opportunities for fresh candidates. The advertisement clarified that such appointments are stop-gap arrangements until regular recruitment is undertaken by the OPSC, granting the department significant discretion in appointments and terminations.

It was further submitted that there was no question of termination, as these individuals belong to the OMHS cadre and will revert to their parent cadre. However, by not applying for vacant Associate Professor posts, they block Assistant Professor positions, preventing fresh recruits from entering government service while avoiding transfers to other medical colleges.

Previously, the Court in its order dated 20.05.2024, directed that the selection process may proceed, but the posts currently occupied by the petitioner would not be filled without permission of this Court.

After hearing the counsel for both parties, the Court noted that the petitioner was appointed as Assistant Professor at MKCG Medical College on deputation basis through a DMET-conducted interview to fulfill NMC-mandated teaching staff requirements. “His appointment, being contractual and temporary, was liable to termination as per its terms. The matter of his replacement is immaterial and extraneous to the issue at hand,” the Court noted.

“This Court finds merit in the argument of the Opposite Party No.4 that the Petitioner No.1’s return to his parent cadre does not constitute termination. Furthermore, the Petitioner No.1( the doctor) has not applied for vacant Associate Professor posts in other Government Colleges, blocking opportunities for fresh candidates and hindering compliance with NMC requirements,” it further observed.

While discussing the key issue of whether the State has any legal authority to advertise the petitioner’s post for fresh recruitment and, consequently terminate his service, the Court concluded, “This Court concludes that an employer’s right to terminate an employee’s service in accordance with the terms of the contract is well-established. The nature of tenure—permanent or temporary—does not diminish the employer’s authority to act within contractual bounds.”

“This Court finds no evidence of discriminatory practices or a breach of Article 16 of the Constitution. Even if specific successors were predetermined, Article 16 would not apply. The Petitioner No.1’s claim that he cannot be replaced by another contractual employee is unsustainable, as he is on a deputation from the DHS/OMHS cadre. His appointment was temporary, to meet NMC requirements, and his deputation concluded on 30.01.2024. The Petitioner No.1 is not being terminated but he is sought to be repatriated to his parent cadre,” concluded the High Court bench.

Further, the Court observed that it is a well-established principle that a contractual employee cannot be terminated solely to appoint another contractual employee.

“However, this principle does not apply in the present case, as the petitioner was not terminated but sought to be repatriated to his parent cadre upon the conclusion of his deputation on 30.01.2024. The Petitioner No.1’s engagement was temporary, aligned with NMC requirements, and explicitly subject to the terms of deputation. With the end of his tenure, the Petitioner No.1 retains the opportunity to apply for the higher post of Associate Professor in accordance with applicable guidelines, ensuring no violation of service principles of jurisprudence,” the Court noted, while dismissing the plea.

At this outset, the Court underscored that the persistent practice of appointing contractual employees to positions such as Assistant Professor in medical colleges is unsustainable. It mentioned that these posts must be filled through regular appointments to ensure the integrity and stability of the academic and medical framework and directed the Government to ensure that “OPSC initiates the recruitment process as expeditiously as possible for filling these positions with regular appointees, thereby addressing the prevailing culture of complacency and ad-hoc arrangements in public service.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/orissa-hc-263721.pdf

Also Read: Release Yearly UPSC Vacancies for Regular Faculty Positions in Medical Colleges: Doctors Tell Health Minister

Powered by WPeMatico

NEET PG Counselling: MCC opens Resignation Window for Round 1 Candidates

Delhi: The Medical Counselling Committee (MCC) has notified regarding the resignation facility for NEET PG candidates who were allotted seats in Round 1 of the All India Quota (AIQ) counselling but have also secured seats through their respective state counselling processes.

This decision comes after numerous requests from candidates who were allotted seats through the MCC but subsequently received offers from their respective state counseling authorities.

Also Read: NEET PG 2024: MCC Begins Round 2 Counselling, Choice Filling, Locking Open Until December 9

As per the notice by MCC, the resignation facility for Round-1 PG seats will be available for a limited time. The resignation facility is available starting today, December 7, 2024, at 5:00 PM and will remain open until 6:00 PM on December 9, 2024 (Monday). This three-day window allows eligible candidates to vacate their seats and ensure that the process is carried out smoothly.

The colleges and institutions where the candidates are allotted seats are required to ensure that all resignations are entered into the IntramCC portal. Failure to do so will result in the resignation being treated as “Null & Void”. This means that the candidate will still be considered as holding the seat, and the resignation will not be processed.

Also Read: NEET Counselling 2024: MCC Announces Total Admitted MBBS, BDS, BSc Nursing Candidates List

The Medical Counselling Committee (MCC) is an organization under the Directorate General of Health Services (DGHS), which operates within the Ministry of Health and Family Welfare, Government of India. MCC plays a key role in the allocation of seats for undergraduate, postgraduate, and super-specialty medical and dental courses in government-run and aided colleges, as well as deemed-to-be-university institutions. The Directorate General of Health Services is responsible for conducting online counseling for the 15% All India Quota (AIQ) seats for undergraduate courses, 50% AIQ seats for postgraduate courses, and 100% seats in super-specialty courses (DM/MCh). This process is carried out following various Gazette notifications from the National Medical Commission (NMC), court rulings, and notifications issued by the Ministry of Health and Family Welfare

To view the notice, click on the link below:

Powered by WPeMatico

NMC releases MARB guidelines, invites applications for new medical colleges, MBBS seat increase

Through a recent notice, the Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) has invited applications for the Establishment of a New Medical college or institution intending to offer MBBS courses and increase the number of UG seats in an established Medical college or Institution for the Academic year (AY)2025-2026.

With this, the NMC has notified the “MARB Guidelines for assessment of medical college and institutions 2024”. The guidelines specify the procedure for applying for MBBS and PG medical courses, assessment, applications and evaluation of the applications along with guidelines for identifying fake patients and the code of conduct for the assessors.

For more information, click on the link below:

Powered by WPeMatico

Pfizer Gets CDSCO Panel Nod To Import 20 Valent Pneumococcal Conjugate Vaccine

New Delhi: Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import the 20-Valent Pneumococcal Conjugate Vaccine (20vPnC).

This came after the vaccine major Pfizer presented the global immunogenicity data of all subjects vis-à-vis immunogenicity data of Indian subjects for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) and the immunogenicity data of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 13 valent.

The pneumococcal 20-valent conjugate vaccine is an active immunizing agent used to prevent infection caused by certain types of pneumococcal bacteria (Streptococcus pneumoniae).

Pneumococcal bacteria are one of the most common causes of pneumonia. Pneumococcal conjugate vaccine can prevent pneumococcal disease. Pneumococcal disease refers to any illness caused by pneumococcal bacteria. These bacteria can cause many types of illnesses, including pneumonia, which is an infection of the lungs.

At the recent SEC meeting for Vaccine held on 26th November 2024, the expert panel reviewed the global immunogenicity data of all subjects vis-à-vis immunogenicity data of Indian subjects for the 20-valent Pneumococcal Conjugate Vaccine (20vPnC) and the immunogenicity data of the pneumococcal polysaccharide conjugate Vaccine (Adsorbed) I.P. 13 valent

After detailed deliberation and based on the data presented, the committee noted the results and recommended the grant of import permission of 20-Valent Pneumococcal Conjugate Vaccine (20vPnC).

Also Read: Abbott Healthcare Gets CDSCO Panel Nod To Manufacture Market Ursodeoxycholic acid for Obstetric Cholestasis

Powered by WPeMatico

Gujarat Medical Council suspends doctor over fake qualifications, alleged negligence

Holding a Surat-based doctor guilty of providing negligent treatment leading to a patient’s death and misrepresenting his qualifications, the Gujarat Medical Council (GMC) has suspended the medical registration of the said doctor for six months.

According to recent media reports, the Council found out that the accused doctor misrepresented his degrees and claimed to possess an MD degree in modern medicine despite possessing only an MBBS degree.

For more information, click on the link below:

Powered by WPeMatico